Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)

NCT00395603 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

550

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated early due to poor recruitment.

Conditions

Cardiovascular Diseases
Diabetes Mellitus

Interventions

DRUG: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks
DRUG: Comparator: atorvastatin / Duration of Treatment: 6 Weeks

Sponsor

Organon and Co